Morria Biopharmaceuticals
Plc


 


a Company under the laws
of england and wales


 


SUBSCRIPTION AGREEMENT


AND INVESTMENT REPRESENTATION


 


		1.	SUBSCRIPTION.



 


		1.1.	Subscription. The undersigned ("Buyer"), intending to be legally bound, hereby
subscribes for and agrees to purchase seventeen thousand five hundred (17,500) ordinary shares of £GBP0.01 (the “Shares”)
of Morria Biopharmaceuticals PLC., a public company under the laws of England and Wales with company number 05252842 whose registered
office is at Thames House, Portsmouth Road, Esher, Surrey, KT10 9AD, UK (the “Company”), and eight thousand seven hundred
and fifty (8,750) warrants to purchase ordinary shares (in the form attached hereto as Exhibit A, the “Warrants”; the
Shares and the Warrants to be issued along with the Shares in the ratio of half Warrant for each one Share purchased, hereinafter,
the “Units”) in a transaction exempt from the registration requirements of the US Securities Act of 1933, as amended
(the “Securities Act”). The purchase price to be remitted to the Company in exchange for the Units shall be an aggregate
of US$35,000 (thirty five thousand US Dollars) (the “Aggregate Subscription”) or US$2.00 (two US Dollars) per Unit
(the “Purchase Price Per Unit”). The exercise price of the Warrant shall be US$2.00 (two US Dollars) per share.



 


		1.2.	Delivery. All Shares or American Depositary Shares ("ADSs")
representing the Ordinary Shares, to be issued or held on behalf of the Undersigned hereunder shall be delivered to undersigned
or its designated trustee or beneficiary.



 


		1.3.	Most Favored Nation Provision.



 


		(a)	From the date hereof until the Expiration Date (as defined hereunder), upon any issuance, offer,
sale, grant of any option or right to purchase or other disposition of any equity security or any equity-linked or related security
(including, without limitation, any “equity security” (as that term is defined under Rule 405 promulgated under the
1933 Act), any Convertible Securities, any debt, any preferred stock or any purchase rights (any such issuance, offer, sale, grant,
disposition, announcement or commencement of marketing is referred to as a “Subsequent Placement”), the Buyer
may elect, in its sole discretion, to exchange all or some of the Shares and a proportionate number of Warrants (based on the initial
ratio of Shares to Warrants issued to such Buyer on the date hereof) then held by such Buyer for additional securities (including
any additional securities issued as part of a unit with such security) of the same type issued in such Subsequent Placement (such
exchange to be made at the same time as the closing of such Subsequent Placement), on the same terms and conditions as the Subsequent
Placement, based on the Purchase Price Per Unit multiplied by the number of Shares being exchanged.  By way of example, if
the Company undertakes a Subsequent Placement of convertible debentures and warrants, the Buyer shall have the right to participate
in such Subsequent Placement and use the exchange of its Shares as consideration, on a USD$1 for USD$1 basis, in lieu of cash consideration.
Notwithstanding whether such Subsequent Placement includes customary Beneficial Ownership Limitations, such Buyer’s securities
issued in the Subsequent Placement shall include such limitations so that the Buyer’s beneficial ownership in Ordinary Shares
does not exceed the Maximum Percentage (as defined below). “Expiration Date” means the earlier of (i) the two
year anniversary date of the Effective Date (as defined hereunder) or (ii) the date immediately following the 20 consecutive Trading
Days wherein the trading volume for the Ordinary Shares or ADSs on the Principal Market exceeds USD$100,000 per Trading Day, which
20 consecutive Trading Day period shall have commenced only after the Effective Date. “Effective Date” means
the date that the applicable Registration Statement (required to be filed pursuant to Section 1.6 hereunder) has been declared
effective by the SEC.



 




    	 



    	 



    

 


		(b)	The Company shall provide the Buyer with at least five (5) Trading Days prior notice of the closing
of the Subsequent Placement, which notice shall include written details on the financing so as to confirm the calculations above
to the satisfaction of the Buyer. Notwithstanding anything to the contrary herein in this Section 1.3, this Section 1.3 shall not
apply to an issuance of Excluded Securities (as defined below). “Excluded Securities” means the issuance of
(A) Ordinary Shares or standard options to purchase Ordinary Shares
to directors, officers, employees, consultants or agents of the Company in their capacity as such pursuant to the Company's Approved
Option Plan dated as of August 28, 2007, ("Approved Option Plan"), provided that (1) prior to the Expiration Date
(but not thereafter), all such issuances (taking into account the Ordinary Shares issuable upon
exercise of such options) after the date hereof pursuant to this clause (A) do not, in the aggregate, exceed more than the sum
of 541,000 Ordinary Shares (representing the shares authorized under the Company’s Approved
Option Plan as of the date of this Agreement) and any shares that are issuable in substitution for forfeited options (in each case,
adjusted for stock splits, stock combinations and other similar transactions occurring after the date of this Agreement) and (2)
the exercise price of any such options is not lowered, none of such options are amended to increase the number of shares issuable
thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner that adversely
affects the Buyer; (B) Ordinary Shares issued upon the conversion or exercise of Convertible
Securities (other than standard options to purchase Ordinary Shares issued pursuant to an Approved
Option Plan that are covered by clause (A) above) issued prior to the date hereof, provided that the conversion or exercise (as
the case may be) of any such Convertible Security is made solely pursuant to the conversion or exercise (as the case may be) provisions
of such Convertible Security that were in effect on the date immediately prior to the date of this Agreement, the conversion or
exercise price of any such Convertible Securities (other than standard options to purchase Ordinary
Shares issued pursuant to an Approved Option Plan that are covered by clause (A) above) is not lowered (whether via amendment
or through the operation of the terms of such Convertible Security or any agreement relating thereto, including anti-dilution provisions),
none of such Convertible Securities are (other than standard options to purchase Ordinary Shares
issued pursuant to an Approved Option Plan that are covered by clause (A) above) (nor is any provision of any such Convertible
Securities) amended or waived in any manner (whether by the Company or the holder thereof) to increase the number of shares issuable
thereunder or decrease the conversion or exercise price thereof and none of the terms or conditions of any such Convertible Securities
(other than standard options to purchase Ordinary Shares issued pursuant to an Approved Option
Plan that are covered by clause (A) above) are otherwise materially changed or waived (whether by the Company or the holder thereof)
in any manner that adversely affects any of the Buyer; (C) the Warrants; and (D) the Ordinary Shares issuable upon the exercise
of each of the Warrants ("Warrant Shares").



 




    	- 2 -



    	 



    

 


		1.4.	Per Share Price Protection.



 


		a)	As to the Buyer, from the date hereof until the Expiration Date, if the Subsequent Placement is
for a consideration per share that is less than the Purchase Price Per Unit (adjusted for stock splits, combinations, dividends
and the like occurring after the date of this agreement hereof) (such lesser price is referred to herein as the “Discounted
Per Share Purchase Price”) (the foregoing, a “Dilutive Issuance”), then immediately after such Dilutive
Issuance, the Company shall issue upon request of the Buyer, in its sole discretion, to such Buyer, without the payment of additional
consideration, in connection with such Dilutive Issuance, a number of additional Ordinary Shares equal to the product of (i) the
fraction obtained by dividing (A) the sum of the number of Initial Shares (as defined below) and Additional Shares (as defined
below) then held by such Buyer on the date of the Dilutive Issuance by (B) the sum of the number of Initial Shares issued to such
Buyer on the Closing Date and all Additional Shares issued to such Buyer after the Closing Date, multiplied by (ii) the difference
between (A) the aggregate number of Ordinary Shares that would have been issued to such Buyer at the Closing if the applicable
portion of the Purchase Price was divided by the Discounted Per Share Purchase Price minus (B) the aggregate number of Ordinary
Shares equal to the sum of the Initial Shares, plus, to the extent there has been a previous issuance of Additional Shares to such
Buyer, the number of Additional Shares previously issued to such Buyer. Additionally, if the Dilutive Issuance includes any option
or warrant (the “Subsequent Placement Warrants”) to purchase, or sell or grant any right to reprice, or otherwise
dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Ordinary Shares or
securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Ordinary Shares, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into
or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary Shares (“Ordinary Share
Equivalents”) at a warrant percentage coverage greater than as provided in this Agreement (the “Subsequent Placement
Warrant Percentage”), then the Company shall issue to the Buyer receiving Additional Shares a number of additional Warrants
equal to (i) such Buyer’s Shares multiplied by the Subsequent Placement Warrant Percentage less (ii) the aggregate number
of Warrants received at Closing (the “Dilutive Issuance Warrants”). For purposes of this Section 1.4(a), (I)
“Additional Shares” means Ordinary Shares issued to such Buyer pursuant to this Section 1.4 (adjusted for stock
splits, combinations, dividends and the like occurring after the Closing Date); and (II) “Initial Shares” means
the number of Ordinary Shares issued to such Buyer on such Buyer’s Closing (adjusted for stock splits, combinations, dividends
and the like). Upon any issuance of Additional Shares and Dilutive Issuance Warrants hereunder, such Additional Shares and the
Ordinary Shares issuable upon exercise of the Dilutive Issuance Warrants (“Dilutive Issuance Warrant Shares”)
shall be included as Registrable Securities (as defined hereunder). In the event that the Registration Statement is then effective,
the Additional Shares and Ordinary Shares underlying the Dilutive Issuance Warrants shall be issued pursuant to the Registration
Statement free of any restrictions or legends, and be delivered via the DWAC system to a DTC account specified by the Buyer, and
if not, in certificated form. “Registrable Securities” means (i) the Shares, (ii) the Warrant Shares, and (iii)
any capital stock of the Company issued or issuable with respect to the Warrant Shares and the Warrants, including, without limitation,
(1) as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of
capital stock of the Company into which the Shares are converted or exchanged and shares of capital stock of a successor entity
into which the Shares are converted or exchanged, in each case, without regard to any limitations on exercise of the Warrants.



 




    	- 3 -



    	 



    

 


		b)	If Ordinary Shares or Ordinary Share Equivalents are issued for a consideration other than cash,
the per share price shall be the fair value of such consideration as determined in good faith by the Board of Directors of the
Company. For the purposes of this Section 1.4, the “price per share for which one Ordinary Share is issuable upon the conversion,
exercise or exchange of any Ordinary Share Equivalents” shall be equal to the sum of the lowest amounts of consideration
(if any) received or receivable by the Company with respect to one Ordinary Shares upon the issuance or sale of such Ordinary Share
Equivalents and upon conversion, exercise or exchange of such Ordinary Share Equivalents. The Company may not refuse to issue to
a Buyer Additional Shares hereunder based on any claim that such Buyer or anyone associated or affiliated with such Buyer has been
engaged in any violation of law, agreement or for any other reason, unless, an injunction from a court, on notice, restraining
and or enjoining an issuance hereunder shall have been sought and obtained. Nothing herein shall limit a Buyer’s right to
pursue actual damages for the Company’s failure to deliver Additional Shares hereunder, and such Buyer shall have the right
to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief.



 


		c)	The Company shall provide each Buyer with at least five (5) Trading Days prior notice of the closing
of the Subsequent Placement, which notice shall include written details on the financing so as to confirm the calculations above
to the satisfaction of the Buyer. Notwithstanding anything to the contrary herein in this Section 1.4, this Section 1.4 shall not
apply to an issuance of Excluded Securities. The Company acknowledges and agrees that the right set forth in this Section 1.4 is
a right granted by the Company, separately, to each Buyer.



 


		1.5.	Acceptance or Rejection.



 


		(a)	The undersigned understands and agrees that the Company reserves the right to reject this subscription
for the Units if, in its reasonable judgment, it deems such action in the best interest of the Company, at any time prior to the
Closing, notwithstanding prior receipt by the undersigned of notice of acceptance of the undersigned's subscription.



 


		(b)	The undersigned understands and agrees that its subscription for the Units is irrevocable.



 


		1.6.	Registration Rights. The Company will file with the SEC a "resale registration statement"
on Form F-1 covering the resale of the Ordinary Shares issued at the Closing and the Ordinary Shares issuable upon exercise of
the Warrants (the "Registration Statement"), no later than the 30th (thirty) calendar day after February 28,
2013 (the "Filing Date"), and use its commercially reasonable efforts to cause the Registration Statement to be declared
effective within 90 (ninety) calendar days after the Filing Date, or within 135 (one hundred and thirty five) calendar days after
the Filing Date in the event the Registration Statement is reviewed by the US Securities and Exchange Commission ("SEC")
(the "Effective Date"), provided that if the Company is required to include audited financial statements for fiscal year
2012 in such Registration Statement, then the Filing Date shall be 60 (sixty) calendar days and Effective Date shall be 165 (one
hundred and sixty five) calendar days if the Registration Statement is reviewed by the SEC.



 


		2.	CLOSING. The closing (the "Closing") of the purchase and sale of the Units, shall
occur simultaneously with 1) the acceptance by the Company (i) of the undersigned's subscription, as evidenced by the Company's
execution of this Subscription Agreement (ii) the Company's Board of Directors' approval of this Agreement, and 2) receipt of the
full Aggregate Subscription.



 


		3.	REPRESENTATIONS AND WARRANTIES.



 


		3.1.	Investor Representations and Warranties. The undersigned hereby acknowledges, represents
and warrants to, and agrees with, the Company and its affiliates as follows:



 


		(a)	Investment Purposes. The undersigned is acquiring the Units for his own account as principal,
not as a nominee or agent, for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization
thereof in whole or in part and no other person has a direct or indirect beneficial interest in such Units or the Shares or Warrants
included therein or any portion thereof. Further, the undersigned does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Units for
which the undersigned is subscribing or any part of the Units or the Shares or Warrants included therein.



 




    	- 4 -



    	 



    

 


		(b)	Authority. The undersigned has full power and authority to enter into this Agreement, the
execution and delivery of this Agreement has been duly authorized, if applicable, and this Agreement constitutes a valid and legally
binding obligation of the undersigned.



 


		(c)	No General Solicitation. The undersigned is not subscribing for the Units as a result of
or subsequent to any advertisement, article, notice or other communication published in any newspaper, magazine or similar media
or broadcast over television or radio, or presented at any seminar or meeting, or any solicitation of a subscription by person
previously not known to the undersigned in connection with investment securities generally.



 


		(d)	Investment Experience. The undersigned is (i) experienced in making investments of the kind
described in this Agreement, (ii) able, by reason of the business and financial experience of its officers (if an entity) and professional
advisors (who are not affiliated with or compensated in any way by the Company or any of its affiliates or selling agents), to
protect its own interests in connection with the transactions described in this Agreement, and (iii) able to afford the entire
loss of its investment in the Units or the Shares or Warrants included therein.



 


		(e)	Exemption from Registration. The undersigned acknowledges his understanding that the offering
and sale of the Units or the Shares or Warrants included therein is intended to be exempt from registration under the Securities
Act. In furtherance thereof, in addition to the other representations and warranties of the undersigned made herein, the undersigned
further represents and warrants to and agrees with the Company and its affiliates as follows:



 


		(i)	The undersigned realizes that the basis for the exemption may not be present if, notwithstanding
such representations, the undersigned has in mind merely acquiring the Units or the Shares or Warrants included therein for a fixed
or determinable period in the future, or for a market rise, or for sale if the market does not rise. The undersigned does not have
any such intention;



 


		(ii)	The undersigned has the financial ability to bear the economic risk of his investment, has adequate
means for providing for his current needs and personal contingencies and has no need for liquidity with respect to his investment
in the Company;



 


		(iii)	The undersigned has such knowledge and experience in financial and business matters as to be capable
of evaluating the merits and risks of the prospective investment in the Units. The undersigned also represents it has not been
organized for the purpose of acquiring the Units; and



 


		(iv)	The undersigned has been provided an opportunity for a reasonable period of time prior to the date
hereof to obtain additional information concerning the offering of the Units, the Company and all other information to the extent
the Company possesses such information or can acquire it without unreasonable effort or expense.



 


		(f)	Economic Considerations. The undersigned is not relying on the Company, or its affiliates
or agents with respect to economic considerations involved in this investment. The undersigned has relied solely on its own advisors.



 


		(g)	No Other Company Representations. No representations or warranties have been made to the
undersigned by the Company, or any officer, employee, agent, affiliate or subsidiary of the Company, other than the representations
of the Company contained herein, and in subscribing for Units, the undersigned is not relying upon any representations other than
those contained herein.



 




    	- 5 -



    	 



    

 


		(h)	Restrictive Legends. Each certificate representing the Shares, and each Warrant agreement
provided to the undersigned shall be endorsed with the following legend, in addition to any other legend required to be placed
thereon by applicable country, federal or state securities laws:



 


“THESE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY OTHER JURISDICTION. THEY MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES
UNDER SUCH ANY OF SUCH ACTS OR LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
OR UNLESS TRANSFERRED PURSUANT TO ANY VALID EXEMPTION FROM REGISTRATION AVAILABLE UNDER SUCH ACT OR ANY OTHER LAWS.”


 


The undersigned consents to the
Company making a notation on its records or giving instructions to any transfer agent of the Company in order to implement the
restrictions on transfer of the Shares and Warrants set forth in this Section.


 


		(i)	Accredited Investor. The undersigned is an “accredited investor” as that term
is defined in Rule 501 of the General Rules and Regulations under the Securities Act by reason of Rule 501(a)(3).



 


		(j)	Potential Loss of Investment; Risk Factors. The undersigned understands that an investment
in the Units is a speculative investment which involves a high degree of risk and the potential loss of his entire investment.
The undersigned understands that the following factors, among others, could cause the loss of any or all of his investment.



 


		(i)	The Company is a development stage company with no operating history for the undersigned to evaluate
its business. The Company was established under the laws of England and Wales in 2004, and has never earned revenue from the sale
of products or services. Because the Company has no operating history and no products ready to be marketed, either now or in the
foreseeable future, it is difficult to evaluate when the Company will reach profitability, if ever. The undersigned has also considered
the uncertainties and difficulties frequently encountered by companies, such as the Company, in similar stages of product development.
The Company is now and for the foreseeable future completely reliant on investment capital for its continued operations. Unavailability
of such investment may jeopardize the Company’s existence resulting in a total of the undersigned’s investment.



 


		(ii)	The Company currently does not have enough working capital to satisfy its capital needs for its
development programs. The Company is dependent upon its management team to fund its ongoing operations, and cannot be certain that
future financing will be available to it on acceptable terms when it needs it. The Company can give no assurances that it will
be able to sell any portion of this offering or that management will continue to fund its ongoing operations. This, along with
the possibility of other factors and circumstances the Company cannot predict, may require it to seek additional financing faster
than anticipated. If the Company is unable to obtain financing to meet its needs, the undersigned may lose of his investment.



 




    	- 6 -



    	 



    

 


		(iii)	Management has no track record of success in the industry in which the Company intends to operate.
This lack of experience may result in the Company’s needing to employ outside experts that have such experience. The additional
cost could result in a net operating loss and, ultimately, could result in the Company's failure. Management's inexperience may
limit the Company’s ability to generate revenues. The Company may never achieve successful operations, and the undersigned
may lose his entire investment.



 


		(iv)	The Company is incorporated under the law of England and Wales. As such the rights and obligations
of shareholders may be different from those rights to which the undersigned is accustomed. The undersigned understands that enforcing
or benefiting from such rights may impose additional costs upon the undersigned.



 


		(k)	Investment Commitment. The undersigned's overall commitment to investments which are not
readily marketable is not disproportionate to the undersigned's net worth, and an investment in the Units will not cause such overall
commitment to become excessive.



 


		(l)	Receipt of Information. The undersigned has received all documents, records, books and other
information pertaining to the undersigned’s investment in the Company that has been requested by the undersigned.



 


		(m)	Investor Questionnaire. The undersigned represents and warrants to the Company that all
information that the undersigned has provided to the Company, including, without limitation, the information in the Investor Questionnaire
attached hereto or previously provided to the Company (the “Investor Questionnaire”), is correct and complete
as of the date hereof.



 


		(n)	No Reliance. Other than as set forth herein, the undersigned is not relying upon any other
information, representation or warranty by the Company or any officer, director, stockholder, agent or representative of the Company
in determining to invest in the Shares. The undersigned has consulted, to the extent deemed appropriate by the undersigned, with
the undersigned’s own advisers as to the financial, tax, legal and related matters concerning an investment in the Units
and on that basis believes that his or its investment in the Units is suitable and appropriate for the undersigned.



 


		(o)	No Governmental Review. The undersigned is aware that no federal or state agency of the
United States or any other jurisdiction has (i) made any finding or determination as to the fairness of this investment, (ii) made
any recommendation or endorsement of the Units or the Company, or (iii) guaranteed or insured any investment in the Units or any
investment made by the Company.



 


		(p)	Price of Units. The undersigned understands that the price of the Units offered hereby bear
no relation to the assets, book value or net worth of the Company and were determined arbitrarily by the Company. The undersigned
further understands that there is a substantial risk of further dilution on his or its investment in the Company.



 


		3.2.	Company’s Representations and Warranties. The Company represents and warrants to the
undersigned as follows:



 


		(a)	Organization of the Company. The Company is a corporation duly organized and validly existing
and in good standing under the laws of England and Wales.



 




    	- 7 -



    	 



    

 


		(b)	Authority. (i) The Company has the requisite corporate power and authority to enter into
and perform its obligations under this Agreement and to issue the Shares and the Warrants in accordance with the terms hereof;
(ii) the execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby
have been duly authorized by all necessary corporate action and no further consent or authorization of the Company or its Board
of Directors or stockholders is required; and (iii) this Agreement has been duly executed and delivered by the Company and constitutes
a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors'
rights and remedies or by other equitable principles of general application.



 


		(c)	Exemption from Registration; Valid Issuances. The sale and issuance of the Units and the
Shares and Warrants included therein, in accordance with the terms and on the bases of the representations and warranties of the
undersigned set forth herein, may and shall be properly issued by the Company to the undersigned, pursuant to the laws of the United
Kingdom and the Articles of Association of the Company. When issued and paid for as herein provided, the Shares shall be duly and
validly issued, fully paid, and nonassessable. Neither the sales of the Shares and Warrants pursuant to, nor the Company's performance
of its obligations under, this Agreement shall (i) result in the creation or imposition of any liens, charges, claims or other
encumbrances upon the Shares or any of the assets of the Company, or (ii) entitle the other holders of the Shares of the Company
to preemptive or other rights to subscribe to or acquire the Ordinary Shares or other securities of the Company. The Shares shall
not subject the undersigned to personal liability by reason of the ownership thereof.



 


		(d)	Currently, the Ordinary Shares are not trading. The Company expects that American Depositary Shares
("ADSs") representing the Ordinary Shares will be quoted on the Over-the-Counter Bulletin Board or other over-the-counter
market following the closing of this Offering. If the Company's ADSs are quoted for trading, the Company's depositary will deliver
ADSs to a holder of Ordinary Shares or the holder's broker that deposits unrestricted Ordinary Shares or evidence of rights to
receive unrestricted Ordinary Shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such
as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names requested
by such holder of Ordinary Shares and will deliver the ADSs to or upon the order of the person or persons entitled thereto.



 


		(e)	No General Solicitation or Advertising in Regard to this Transaction. Neither the Company
nor any of its affiliates nor any person acting on its or their behalf (i) has conducted or will conduct any general solicitation
(as that term is used in Rule 502(c) of Regulation D) or general advertising with respect to any of the Units, or (ii) made any
offers or sales of any security or solicited any offers to buy any security under any circumstances that would require registration
of the Ordinary Shares under the Securities Act.



 




    	- 8 -



    	 



    

 


		(f)	Listing or Quotation. As promptly as practicable after the date of this agreement hereof,
but in no event later than the six (6) month anniversary of the date of this agreement hereof (the “Listing Date”),
the Company shall take all necessary actions to obtain listing or quotation for trading of the Ordinary
Shares or American depositary shares or receipts representing the Ordinary Shares (the “ADSs”) on the
OTC Bulletin Board (or any successor) (the “Principal Market”). In addition to such Buyer’s other available
remedies, in the event that, on the Listing Date, the Company has not obtained listing or quotation for trading of the Ordinary
Shares or ADSs on the Principal Market, the Company shall pay to each Buyer, in cash, as partial liquidated damages and not as
a penalty, an amount per day equal to 0.33% of such Buyer’s Subscription Amount until the date that the Ordinary Shares or
ADSs are listed or designated for quotation on the Principal Market. Nothing herein shall limit such Buyer’s right to pursue
actual damages for the Company’s failure to secure listing or designated for quotation of its Ordinary Shares or ADSs, and
such Buyer shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief. If the Ordinary Shares or ADSs becomes listed
or designated for quotation on any other Eligible Market (as defined below), then the Company shall promptly secure the listing
or designation for quotation (as the case may be) of all of the Registrable Securities (or ADSs representing such Registrable Securities)
upon each national securities exchange and automated quotation system, if any, upon which the Ordinary
Shares or ADSs are then listed or designated for quotation (as the case may be) (subject to official notice of issuance)
and shall maintain such listing or designation for quotation (as the case may be) of all Registrable Securities (or ADSs representing
such Registrable Securities) from time to time issuable under the terms of this agreement on such then applicable national securities
exchange or automated quotation system. The Company shall take all necessary actions to maintain the Ordinary
Shares’ (or ADSs representing such Registrable Securities) trading on the Principal Market. If in the future, the
Ordinary Shares or ADSs become listed or designated for quotation on any of The New York Stock
Exchange, the NYSE Amex, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (each, together
with the Principal Market, an “Eligible Market”), the Company shall maintain the Ordinary
Shares of ADSs’ listing or designation for quotation (as the case may be) on such market. Neither the Company nor
any of its Subsidiaries shall take any action which could be reasonably expected to result in the delisting or suspension of the
Ordinary Shares or ADSs on an Eligible Market on which the Ordinary
Shares or ADSs are then traded, listed or designated for quotation. The Company shall take such actions and do all things
reasonably necessary or appropriate to assist the Buyer in exchanging any Shares or Warrant Shares for ADSs. The Company shall
pay all fees and expenses in connection with satisfying its obligations under this Section 3.2(f).



 


		4.	INDEMNITY. The undersigned agrees to indemnify and hold harmless the Company, its officers and
directors, employees and its affiliates and their respective successors and assigns and each other person, if any, who controls
any thereof, against any loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all expenses
whatsoever reasonably incurred in investigating, preparing or defending against any litigation commenced or threatened or any claim
whatsoever) arising out of or based upon any false representation or warranty or breach or failure by the undersigned to comply
with any covenant or agreement made by the undersigned herein or in any other document furnished by the undersigned to any of the
foregoing in connection with this transaction.



 


		5.	GENERAL.



 


		5.1.	Modification. Neither this Agreement nor any provisions hereof shall be modified, discharged
or terminated except by an instrument in writing signed by the party against whom any waiver, change, discharge or termination
is sought.



 


		5.2.	Notices. Any notice, demand or other communication which any party hereto may be required,
or may elect, to give to anyone interested hereunder shall be sufficiently given if (a) deposited, postage prepaid, in a United
States mail letter box, registered or certified mail, return receipt requested, addressed to such address as may be given herein,
or (b) delivered personally at such address.



 


		5.3.	Counterparts. This Agreement may be executed through the use of separate signature pages
or in any number of counterparts and by facsimile, and each of such counterparts shall, for all purposes, constitute one agreement
binding on all parties, notwithstanding that all parties are not signatories to the same counterpart. Signatures may be facsimiles.



 




    	- 9 -



    	 



    

 


		5.4.	Binding Effect. Except as otherwise provided herein, this Agreement shall be binding upon
and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives and assigns.
If the undersigned is more than one person, the obligation of the undersigned shall be joint and several and the agreements, representations,
warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and his heirs,
executors, administrators and successors.



 


		5.5.	Entire Agreement. This Agreement and the documents referenced herein contain the entire
agreement of the parties and there are no representations, covenants or other agreements except as stated or referred to herein
and therein.



 


		5.6.	Assignability. This Agreement is not transferable or assignable by the undersigned.



 


		5.7.	Applicable Law. This Agreement shall be governed by and construed in accordance with the
laws of the United Kingdom, without giving effect to conflicts of law principles.



 


		5.8.	Pronouns. The use herein of the masculine pronouns "him" or "his" or
similar terms shall be deemed to include the feminine and neuter genders as well and the use herein of the singular pronoun shall
be deemed to include the plural as well.



 


		5.9.	Further Assurances. Upon request from time to time, the undersigned shall execute and deliver
all documents, take all rightful oaths and do all other acts that may be necessary or desirable, in the reasonable opinion of the
Company or its counsel, to effect the subscription for the Shares in accordance herewith.



 


		5.10.	Company wire-transfer details: The Aggregate Subscription shall be transferred to the bank
account details as follows:



 


	Morria Biopharmaceuticals PLC	Chase Morria PLC USA
	 	11 West 51st street, New York, 10019, NY. USA
	1500 Broadway	Routing - 021000021
	New York, NY 10036	Checking  - 453746518
	 	SWIFT: CHASUS33XXX


 


[Remainder of page intentionally left
blank]


 




    	- 10 -



    	 



    

 


IN WITNESS WHEREOF, the undersigned has
executed this Agreement on the 31st day of January, 2013.


 


Amount of Investment: US $35,000


 


INDIVIDUAL INVESTOR:


 


	Signature:	/s/ Mark S. Cohen	 


Name: Mark S. Cohen


Address:


PEARL COHEN ZEDEK LATZER

5 Shenkar Street

P.O. Box 12704

Herzlia 46733 Israe


 


PARTNERSHIP, CORPORATION, TRUST,


CUSTODIAL ACCOUNT, OTHER INVESTOR


 


______________________________


  (Name of Entity)


By: __________________________


Name:


Title:


Address:


 


ACCEPTANCE OF SUBSCRIPTION


 


(to be filed out only by the Company)


 


The Company hereby accepts the above application
for subscription for Units on behalf of the Company.


 


Dated: January 31, 2013


 


	    /s/ Dov Elefant	 
	Dov Elefant, Chief Financial Officer	 


 




    	- 11 -



    	 



    

 


INVESTOR QUESTIONNAIRE


 


A. General Information


 


1.  Print Full Name of Investor:


- Individual:


 


Mark S. Cohen


First, Middle, Last


 


- Partnership, Corporation, Trust, Custodial
Account, Other:


_______________________________


Name of Entity


 


2.  Address for Notices:


PEARL COHEN ZEDEK LATZER

5 Shenkar Street

P.O. Box 12704

Herzlia 46733 Israel


 


3.  Name of Primary Contact Person: ___________________


Title: ____________________________________________


 


4.  Telephone Number: ______________________________


 


5.  E-Mail Address: _________________________________


 


6.  Facsimile Number: _______________________________


 


7.  Permanent Address:


(if different from Address for Notices
above)


 


______________________________


 


______________________________


 


______________________________


 


______________________________


 


______________________________


 


8.  Authorized Signatory: __________________________________


  Title: ________________________________________________


  Telephone Number: _____________________________________


  Facsimile Number: ____________________________________


 




    	- 12 -



    	 



    

 


B. Accredited Investor Status


 


The Investor represents and warrants that
the Investor is an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act of
1933, as amended (the “Securities Act”), and has checked the box or boxes below which are next to the categories under
which the Investor qualifies as an accredited investor:


 


FOR INDIVIDUALS:


 


		_____	A natural person with individual net worth (or joint net worth with spouse) in excess of $1 million.
For purposes of this item, “net worth” means the excess of total assets at fair market value, over total liabilities,
except that the fair market value of the principal residence owned by a natural person shall be excluded for purposes of determining
such natural person’s net worth. Notwithstanding the foregoing, the related amount of indebtedness secured by the primary
residence up to the fair market value of such residence may be excluded from the calculation of net worth, but indebtedness secured
by the primary residence in excess of the fair market value of such residence should be considered a liability and deducted from
the natural person’s net worth. The principal residence owned by a natural person shall be valued either (a) at cost, including
the cost of improvements, net of current encumbrances upon the property, or (b) at the appraised value of the residence as determined
upon a written appraisal used by an institutional lender making a loan to the individual secured by the property, including the
cost of subsequent improvements, net of current encumbrances upon the property. As used in the preceding sentence, “institutional
lender” means a bank, savings and loan company, industrial loan company, credit union or personal property broker or a company
whose principal business is as a lender of loans secured by real property and which has such loans receivable in the amount of
USD$2,000,000 of more.



 


		_____	A natural person with individual income (without including any income of the Investor’s spouse)
in excess of USD$200,000, or joint income with spouse of $300,000, in each of the two most recent years and who reasonably expects
to reach the same income level in the current year.



 


FOR ENTITIES:


 


		_____	A bank as defined in Section 3(a)(2) of the Securities Act or any savings and loan association
or other institution as defined in Section 3(a)(5)(A) of the Securities Act, whether acting in its individual or fiduciary capacity.



 


		_____	An insurance company as defined in Section 2(13) of the Securities Act.



 


		_____	A broker-dealer registered pursuant to Section 15 of
the Securities Exchange Act of 1934.



 


		_____	An investment company registered under the Investment Company Act of 1940, as amended (the “Investment
Company Act”).



 


		_____	A business development company as defined in Section 2(a)(48) of the Investment Company Act.



 


		_____	A small business investment company licensed by the Small Business Administration under Section
301(c) or (d) of the Small Business Investment Act of 1958.



 


		_____	A private business development company as defined in Section 202(a)(22) of the Investment Advisers
Act of 1940. If an Investor has checked this box, please contact Mark Cohen, Esq. at 646-878-0800 for additional information that
will be required.



 




    	- 13 -



    	 



    

 


		_____	An organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, Massachusetts
or similar business trust, or partnership, not formed for the specific purpose of acquiring the Units, with total assets in excess
of $5 million.



 


		_____	A trust with total assets in excess of $5 million not formed for the specific purpose of acquiring
the Units, whose purchase is directed by a person with such knowledge and experience in financial and business matters as to be
capable of evaluating the merits and risks of an investment in the Company and the purchase of the Units and the Shares and Warrant
included therein.



 


		_____	An employee benefit plan within the meaning of ERISA if the decision to invest in the Units is
made by a plan fiduciary, as defined in Section 3(21) of ERISA, which is either a bank, savings and loan association, insurance
company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5 million or, if a self-directed
plan, with investment decisions made solely by persons that are accredited investors.



 


		_____	A plan established and maintained by a state, its political subdivisions, or any agency or instrumentality
of a state or its political subdivisions, for the benefit of its employees, if the plan has total assets in excess of $5 million.



 


		_____	An entity, including a grantor trust, in which all of the equity owners are accredited investors
as determined under any of the foregoing paragraphs (for this purpose, a beneficiary of a trust is not an equity owner, but the
grantor of a grantor trust is an equity owner).



 


The Investor understands that the foregoing
information will be relied upon by the Company for the purpose of determining the eligibility of the Investor to purchase the Units.
The Investor agrees to notify the Company immediately if any representation or warranty contained in this Subscription Agreement,
including this Investor Questionnaire, becomes untrue at any time. The Investor agrees to provide, if requested, any additional
information that may reasonably be required to substantiate the Investor’s status as an accredited investor or to otherwise
determine the eligibility of the Investor to purchase the Units. The Investor agrees to indemnify and hold harmless the Company
and each officer, director, shareholder, agent and representative of the Company and their respective affiliates and successors
and assigns from and against any loss, damage or liability due to or arising out of a breach of any representation, warranty or
agreement of the Investor contained herein.


 


INDIVIDUAL:


 


___________________________


(Signature)


 


___________________________


(Name)


 


PARTNERSHIP, CORPORATION, TRUST, CUSTODIAL
ACCOUNT, OTHER:


 


____________________________________


(Name of Entity)


 


By: ________________________________


(Signature)


 


____________________________________


(Print Name and Title)


 




    	- 14 -



    	 



    

 


Exhibit A


Form of Warrant


 


THIS WARRANT AND THE ORDINARY SHARES ISSUED
UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"),
OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS
(1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE SECURITIES ACT, OR (B) THE COMPANY SHALL
HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS
AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES OR "BLUE SKY" LAWS.


 


	No. 63 ___	For the Purchase
	 Issue Date: January 31, 2013   	of 8,750 Ordinary Shares


 


WARRANT TO PURCHASE


ORDINARY SHARES


OF


MORRIA BIOPHARMACEUTICALS PLC


 


(A UNITED KINGDOM COMPANY)


 


MORRIA BIOPHARMACEUTICALS PLC.,
a company registered pursuant to the laws of the United Kingdom (the “Company”), for value received, hereby certifies
that Mark S. Cohen (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company,
at any time or from time to time at or before the earlier of 5:00 p.m. (EST) on that date which is five (5) years from the Issue
Date first written above (the “Expiration Date”) and the termination of this Warrant as provided in Section 6 hereof,
eight thousand seven hundred and fifty (8,750) ordinary shares of the Company (the “Ordinary Shares”), at an exercise
price per Ordinary Share equal to US $2.00 (two US Dollars) per share (the “Base Price”), as may be adjusted upon the
occurrence of certain events as set forth in Section 2 of this Warrant. The Ordinary Shares issuable upon exercise of this Warrant,
and the purchase price per share, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,”
respectively.


 


1.          Exercise.


 


1.1          Manner of Exercise: Cash and Cashless.
At the Option of the Holder, the Warrant may be exercised on a cash or cashless basis as follows:


 


(a)          Payment in
Cash. This Warrant may be exercised by the Holder, in whole or in part, by surrendering this Warrant, with the purchase form
appended hereto as Exhibit A duly executed by the Holder, at the principal office of the Company, or at such other place
as the Company may designate, accompanied by payment in full of the Purchase Price payable in respect of the number of Warrant
Shares purchased upon such exercise. Payment of the Purchase Price shall be in cash or by certified or official bank check payable
to the order of the Company.


 




    	- 15 -



    	 



    

 


(b)          Cashless
Exercise. The Holder may, at its option, exchange this Warrant on a cashless basis, in whole or in part (a "Warrant
Exchange"), into the number of Warrant Shares determined in accordance with this Section 1.1(b), by surrendering this
Warrant at the Company’s office, accompanied by an irrevocable notice stating such Holder's intent to effect such exchange,
the number of Warrant Shares to be exchanged and the date of the notice of such intent to exchange (the "Notice of Exchange").
The Warrant Exchange shall take place on the date the Notice of Exchange and this Warrant are received by the Company (the "Exchange
Date"). Certificates for the shares issuable upon such Warrant Exchange and, if applicable, a new warrant of like tenor
evidencing the balance of the shares remaining subject to such Warrant, shall be issued as of the Exchange Date and delivered to
the Holder as soon as is reasonably practicable following the Exchange Date. In connection with any Warrant Exchange, a Warrant
shall represent the right to subscribe for and acquire the number of Warrant Shares (rounded to the next highest integer) equal
to (i) the number of Warrant Shares specified by the Holder in its Notice of Exchange (the "Total Number") less
(ii) the number of Warrant Shares equal to the quotient obtained by dividing (A) the product of the Total Number and the existing
Purchase Price by (B) the current market value of an Ordinary Share. Current market value, for purposes hereof, shall mean (i)
if the Ordinary Shares are then traded or quoted on a securities exchange or an over-the-counter market, the average price on such
exchange or market for the ten business days immediately preceding the date of the Notice of Exchange, and (ii) if the Ordinary
Shares are not then traded or quoted on a securities exchange or an over-the-counter market, the current market value on such date
shall be the fair market value as mutually determined by the Company and the Holder.


 


1.2          Effectiveness. Each exercise
of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this Warrant
shall have been surrendered to the Company as provided in Section 1.1 above. At such time, the person or persons in whose name
or names any certificates for Warrant Shares shall be issuable upon such exercise as provided in Section 1.3 below shall be deemed
to have become the holder or holders of record of the Warrant Shares represented by such certificates.


 


1.3.          Delivery of Certificates. As
soon as practicable after the exercise of this Warrant in full or in part, and in any event within ten (10) business days thereafter,
the Company at its sole expense will cause to be issued in the name of, and delivered to, the Holder, or, subject to the terms
and conditions hereof, as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct:


 


(a)          A certificate or
certificates for the number of full shares of Warrant Shares to which such Holder shall be entitled upon such exercise plus, in
lieu of any fractional share to which such Holder would otherwise be entitled, cash in an amount determined pursuant to Section
1.4 hereof, and


 


(b)          In
case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, setting forth on the face
or faces thereof the number of shares of Warrant Shares (without giving effect to any adjustment therein) equal to the number of
such shares called for on the face of this Warrant minus the number of such shares purchased by the Holder upon such exercise as
provided in Section 1.1 above.


 




    	- 16 -



    	 



    

 


1.4.          Fractional Shares. The Company
shall not be required upon the exercise of this Warrant to issue any fractional shares, but shall make an adjustment therefor
either (i) in cash on the basis of the fair market value of the Warrant Shares reasonably determined by The Board of Directors
of the Company, or (ii) by rounding up the number of shares to the nearest whole number.


 


2.          Certain Adjustments. The Purchase
Price and the number of shares of Warrant Shares deliverable upon exercise of the Warrant shall be subject to adjustment from
time to time as follows:


 


2.1          Subdivision, Consolidation, Reclassification
or Change in Ordinary Shares or Warrant Shares. In the event of any consolidation, reclassification or change of the Ordinary
Shares or Warrant Shares into a lesser number or different class or classes of stock, the number of shares of Warrant Shares deliverable
upon exercise of this Warrant shall be proportionally decreased and the Purchase Price for such Warrant Shares shall be proportionately
increased. In the event of any subdivision, reclassification or change of the Ordinary Shares or Warrant Shares into a greater
number or different class or classes of stock, the number of shares of Warrant Shares deliverable upon exercise of this Warrant
shall be proportionally increased and the Purchase Price for such Warrant Shares shall be proportionately reduced.


 


2.2          Dividends or Other Distributions.
In the event that the Company issues additional Ordinary Shares as a dividend or other distribution with respect to the Ordinary
Shares, the number of shares of Warrant Shares deliverable upon exercise of this Warrant shall be determined in accordance with
the terms of the Certificate of Incorporation, and the Purchase Price for such Warrant Shares shall be proportionately reduced.


 


2.3          Reorganizations. If there shall
occur any capital reorganization of the Ordinary Shares or the Warrant Shares (excluding mergers and consolidations covered under
Section 2.4 hereto and other than a subdivision, combination, reclassification or change in par value), then, as part of any such
reorganization, lawful provision shall be made so that the Holder shall have the right thereafter to receive upon the exercise
of this Warrant the kind and amount of shares of stock or other securities or property which such Holder would have been entitled
to receive if, immediately prior to any such reorganization, such Holder had held the number of Ordinary Shares which were then
purchasable upon the exercise of this Warrant. In any such case, appropriate adjustment (as reasonably determined by the Board
of Directors of the Company) shall be made in the application of the provisions set forth herein with respect to the rights and
interests thereafter of the Holder such that the provisions set forth in this Section 2 (including provisions with respect to
adjustment of the Purchase Price) shall thereafter be applicable, as nearly as is reasonably practicable, in relation to any shares
of stock or other securities or property thereafter deliverable upon the exercise of this Warrant.


 


2.4          Merger, Consolidation or Sale of
Assets. Subject to the provisions of Section 6, if there shall be a merger or consolidation of the Company with or into another
corporation (other than a merger or reorganization involving only a change in the state of incorporation of the Company or the
acquisition by the Company of other businesses where the Company survives as a going concern), or the sale of all or substantially
all of the Company’s capital stock or assets to any other person, then as a part of such transaction, provision shall be
made so that the Holder shall thereafter be entitled to receive the number of shares of stock or other securities or property
of the Company, or of the successor corporation resulting from the merger, consolidation or sale, to which the Holder would have
been entitled if the Holder had exercised its rights pursuant to this Warrant in full immediately prior thereto. In any such case,
appropriate adjustment shall be made in the application of the provisions of this Section 2 to the end that the provisions of
this Section 2 shall be applicable after that event in as nearly equivalent a manner as may be practicable.


 




    	- 17 -



    	 



    

 


2.5          Certificate of Adjustment. When
any adjustment is required to be made in the Purchase Price, the Company shall promptly mail to the Holder a certificate setting
forth the Purchase Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. Delivery
of such certificate shall be deemed to be a final and binding determination with respect to such adjustment unless challenged
by the Holder within ten (10) days of receipt thereof. Such certificate shall also set forth the kind and amount of stock or other
securities or property into which this Warrant shall be exercisable following the occurrence of any of the events specified in
this Section 2.


 


2.6          Subsequent Warrant Sales.
Until the earlier of (i) the two (2) year anniversary date of the Effective Date (as defined in the Subscription Agreement) or
(ii) the date immediately following the 20 consecutive Trading Days wherein the trading volume for the Ordinary Shares or ADSs
on the Principal Market exceeds USD$100,000 per Trading Day, which 20 consecutive Trading Day period shall have commenced only
after the Effective Date, if the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding,
shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce
any offer, sale, grant or any option to purchase or other disposition) any warrants, options or other similar instruments to purchase
Ordinary Shares, at an effective price per share less than the Base Price then in effect (such lower price, the “Lower
Base Share Price” and such issuances collectively, a “Dilutive Issuance”) (it being understood and
agreed that if the holder of the warrants to purchase Ordinary Shares so issued shall at any time, whether by operation of purchase
price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options
or rights per share which are issued in connection with such issuance, be entitled to receive Ordinary Shares at an effective price
per share that is less than the Base Price, such issuance shall be deemed to have occurred for less than the Base Price on such
date of the Dilutive Issuance at such effective price), then simultaneously with the consummation of each Dilutive Issuance, the
Base Price shall be reduced and only reduced to equal to the Lower Base Share Price. Such adjustment shall be made whenever such
warrants to purchase Ordinary Shares are issued. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under
this Section 2.6 in respect of any Excluded Securities. The Company shall notify the Holder, in writing, no later than the third
Trading Day following the issuance or deemed issuance of any warrants to purchase Ordinary Shares subject to this Section 2.6,
indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing
terms (such notice, the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the Company
provides a Dilutive Issuance Notice pursuant to this Section 2.6, upon the occurrence of any Dilutive Issuance, the Holder is entitled
to receive a number of Warrant Shares based upon the Lower Base Share Price regardless of whether the Holder accurately refers
to the Lower Base Share Price in the Notice of Exercise.


 




    	- 18 -



    	 



    

 


3.          Compliance with Securities Act.


 


3.1          Unregistered Securities. The
Holder acknowledges that this Warrant and the Warrant Shares have not been registered under the Securities Act of 1933, as amended,
and the rules and regulations thereunder, or any successor legislation (the “Securities Act”), and agrees not to sell,
pledge, distribute, offer for sale, transfer or otherwise dispose of this Warrant or any Warrant Shares in the absence of (i)
an effective registration statement under the Securities Act covering this Warrant or such Warrant Shares and registration or
qualification of this Warrant or such Warrant Shares under any applicable “blue sky” or state securities law then
in effect, or (ii) an opinion of counsel, satisfactory to the Company, that such registration and qualification are not required.
The Company may delay issuance of the Warrant Shares until completion of any action or obtaining of any consent, which the Company
deems necessary under any applicable law (including without limitation state securities or “blue sky” laws).


 


3.2          Investment Letter. Without limiting
the generality of Section 3.1, unless the offer and sale of any shares of Warrant Shares shall have been effectively registered
under the Securities Act, the Company shall be under no obligation to issue the Warrant Shares unless and until the Holder shall
have executed an investment letter in form and substance satisfactory to the Company, including a warranty at the time of such
exercise that the Holder is acquiring such shares for its own account, for investment and not with a view to, or for sale in connection
with, the distribution of any such shares, and that the Holder is an “accredited investor” as defined in the rules
promulgated under the Securities Act.


 


3.3          Legend. Certificates delivered
to the Holder pursuant to Section 1.3 shall bear the following legend or a legend in substantially similar form:


 


	 	 	“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN TAKEN FOR INVESTMENT AND THEY MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, THAT AN EXEMPTION FROM REGISTRATION IS THEN AVAILABLE.”


 


4.          Reservation of Stock. The Company
agrees that, prior to the expiration of this Warrant, the Company will at all times have authorized and in reserve, and will keep
available, solely for issuance or delivery upon the exercise of this Warrant, the Ordinary Shares and other securities and properties
as from time to time shall be receivable upon the exercise of this Warrant, free and clear of all restrictions on sale or transfer
and free and clear of all preemptive rights and rights of first refusal.


 


5.          Replacement of Warrants. Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in
the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount
reasonably satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company
will issue, in lieu thereof, a new Warrant of like tenor.


 


6.          Termination Upon Certain Events.
If there shall be a merger or consolidation of the Company with or into another corporation (other than a merger or reorganization
involving only a change in the state of incorporation of the Company or the acquisition by the Company of other businesses where
the Company survives as a going concern), or the sale of all or substantially all of the Company’s capital stock (other
than a reverse merger transaction) or assets to any other person, or the liquidation or dissolution of the Company, then as a
part of such transaction, provisions shall be made so that the Holder shall thereafter be entitled to receive the number of shares
of stock or other securities or property of the Company, or of the successor corporation resulting from the merger, consolidation
or sale, to which the Holder would have been entitled if the Holder had exercised its rights pursuant to this Warrant immediately
prior thereto (and, in such case, appropriate adjustment shall be made in the application of the provisions of this Section 6
to the end that the provisions of Section 3 shall be applicable after that event in as nearly equivalent a manner as may be practicable).


 




    	- 19 -



    	 



    

 


7.          Transferability. Without the
prior written consent of the Company, this Warrant shall not be assigned, pledged or hypothecated in any way (whether by operation
of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment,
pledge, hypothecation or other disposition of this Warrant or of any rights granted hereunder contrary to the provisions of this
Section 7, or the levy of any attachment or similar process upon this Warrant or such rights, shall be null and void.


 


8.          No Rights as Stockholder. Until
the exercise of this Warrant, the Holder shall not have or exercise any rights by virtue hereof as a stockholder of the Company.


 


9.          Notices. All notices, requests
and other communications hereunder shall be in writing, shall be either (i) delivered by hand, (ii) made by telex, telecopy or
facsimile transmission, (iii) sent by overnight courier, or (iv) sent by registered mail, postage prepaid, return receipt requested.
In the case of notices from the Company to the Holder, they shall be sent to the address furnished to the Company in writing by
the last Holder who shall have furnished an address to the Company in writing. All notices from the Holder to the Company shall
be delivered to the Company at 53 Davies Street Mayfair, London W1K5JH, England, Attn: President, or such other address as the
Company shall so notify the Holder. All notices, requests and other communications hereunder shall be deemed to have been given
(i) by hand, at the time of the delivery thereof to the receiving party at the address of such party described above, (ii) if
made by telex, telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation
or otherwise, (iii) if sent by overnight courier, on the next business day following the day such notices are delivered to the
courier service, or (iv) if sent by registered mail, on the fifth business day following the day such mailing is made.


 


10.          Amendment, Modification and Waiver.
The Warrants may not be amended or modified, and any provision hereof and thereof may not be waived, without the written consent
of the Holder.


 


11.          Headings. The headings in this
Warrant are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms
or provisions of this Warrant.


 


12.          Governing Law. This Warrant
will be governed by and construed in accordance with and governed by the law of the State of New York, without giving effect to
the conflict of law principles thereof.


 


[Remainder of page intentionally left
blank]


 




    	- 20 -



    	 



    

 


IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed by its authorized officer as of the date first indicated above.


 


	 	MORRIA BIOPHARMACEUTICALS PLC.
	 	 	 
	 	By:	 
	 	Name:	Dov Elefant
	 	Title:	Chief Financial Officer


 




    	- 21 -



    	 



    

 


EXHIBIT A


 


PURCHASE FORM


 


To:          MORRIA BIOPHARMACEUTICALS PLC


 


The undersigned pursuant to the provisions
set forth in the attached Warrant (No. W-____), hereby irrevocably elects to purchase _____________________________________ (_____________)
ordinary shares (the “Ordinary Shares”) of MORRIA BIOPHARMACEUTICALS PLC, covered by such Warrant and herewith makes
payment of US $_____________, representing the full purchase price for such shares at the price per share provided for in such
Warrant. The Ordinary Shares for which the Warrant may be exercised or converted shall be known herein as the “Warrant Shares.”


 


The undersigned is aware that the Warrant
Shares have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”)
or any state securities laws. The undersigned understands that reliance by the Company on exemptions under the Securities Act is
predicated in part upon the truth and accuracy of the statements of the undersigned in this Purchase Form.


 


The undersigned represents and warrants
that it is an “accredited investor” as defined in the rules promulgated under the Securities Act.


 


The undersigned represents and warrants
that (1) it has been furnished with all information which it deems necessary to evaluate the merits and risks of the purchase of
the Warrant Shares, (2) it has had the opportunity to ask questions concerning the Warrant Shares and the Company and all questions
posed have been answered to its satisfaction, (3) it has been given the opportunity to obtain any additional information it deems
necessary to verify the accuracy of any information obtained concerning the Warrant Shares and the Company and (4) it has such
knowledge and experience in financial and business matters that it is able to evaluate the merits and risks of purchasing the Warrant
Shares and to make an informed investment decision relating thereto.


 


The undersigned hereby represents and warrant
that it is purchasing the Warrant Shares for its own account for investment and not with a view to the sale or distribution of
all or any part of the Warrant Shares.


 


The undersigned understands that because
the Warrant Shares has not been registered under the Securities Act, it must continue to bear the economic risk of the investment
for an indefinite period of time and the Warrant Shares cannot be sold unless it is subsequently registered under applicable federal
and state securities laws or an exemption from such registration is available.


 


The undersigned agrees that it will in
no event sell or distribute or otherwise dispose of all or any part of the Warrant Shares unless (1) there is an effective registration
statement under the Securities Act and applicable state securities laws covering any such transaction involving the Warrant Shares,
or (2) the Company receives an opinion satisfactory to the Company of the undersigned’s legal counsel stating that such transaction
is exempt from registration. The undersigned consents to the placing of a legend on its certificate for the Warrant Shares stating
that the Warrant Shares has not been registered and setting forth the restriction on transfer contemplated hereby and to the placing
of a stop transfer order on the books of the Company and with any transfer agents against the Warrant Shares until the Warrant
Shares may be legally resold or distributed without restriction.


 



    	- 22 -



    	 



    

 


The undersigned has considered the federal
and state income tax implications of the exercise of the Warrant and the purchase and subsequent sale of the Warrant Shares.


 


By: ______________________________


Dated: ____________________________


 



    	- 23 -